Inventor · disambiguated record
Yunfei Zhu
Also filed as: ZHU YUNFEI
24 granted patents·13 pending applications·114 citations·filing 2016–2024
95Inventor score
Top patents by PatentIndex Score
37 records- 0197US10981894B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Apr 20, 2021·6 cites·20 claims
- 0296US11186590B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 30, 2021·6 cites·11 claims
- 0395US11834462B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Dec 5, 2023·2 cites·16 claims
- 0495US10766877B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Sep 8, 2020·7 cites·20 claims
- 0595US10604507B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 31, 2020·7 cites·20 claims
- 0695US10562884B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Feb 18, 2020·7 cites·20 claims
- 0794US11566015B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2021·Granted Jan 31, 2023·2 cites·36 claims
- 0894US11479540B2Nonpeptide somatostatin type 5 receptor agonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Oct 25, 2022·5 cites·43 claims
- 0993US12134610B2Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2024·Granted Nov 5, 2024·1 cites·29 claims
- 1093US10875839B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Dec 29, 2020·5 cites·10 claims
- 1193US10696689B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jun 30, 2020·12 cites·8 claims
- 1293US9896432B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2017·Granted Feb 20, 2018·11 cites·20 claims
- 1392US10597377B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 24, 2020·8 cites·9 claims
- 1492US10351547B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2017·Granted Jul 16, 2019·9 cites·24 claims
- 1592US9902703B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2016·Granted Feb 27, 2018·8 cites·17 claims
- 1691US11414397B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Aug 16, 2022·2 cites·23 claims
- 1791US11072598B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jul 27, 2021·6 cites·20 claims
- 1891US9957267B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2016·Granted May 1, 2018·8 cites·22 claims
- 1988US12479828B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Granted Nov 25, 2025·0 cites·22 claims
- 2085US2024109866A1Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2180US11608335B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 21, 2023·2 cites·21 claims
- 2280US2022380337A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2374US2024376067A1Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2474US2022048924A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2574US2024254106A1Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2667US2024285628A1Non-peptide targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2767US2024408247A1Non-peptide targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2866US2022144802A1Nonpeptide somatostatin type 5 receptor agonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2964US2021087165A1Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3061US2025213735A1Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereofRADIONETICS ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 3160US2023159532A1Parathyroid hormone (pth) receptor antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3258US2024226343A1Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereofRADIONETICS ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 3357US2023405157A1Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereofRADIONETICS ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 3454US12492181B2Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Dec 9, 2025·0 cites·21 claims
- 3553US12479825B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 25, 2025·0 cites·19 claims
- 3653US12466829B2Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 11, 2025·0 cites·19 claims
- 3743US11028068B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2018·Granted Jun 8, 2021·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Yunfei Zhu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →